BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 8972563)

  • 1. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
    Prosper F; Stroncek D; Verfaillie CM
    Blood; 1996 Sep; 88(6):2033-42. PubMed ID: 8822922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.
    Dreger P; Haferlach T; Eckstein V; Jacobs S; Suttorp M; Löffler H; Müller-Ruchholtz W; Schmitz N
    Br J Haematol; 1994 Jul; 87(3):609-13. PubMed ID: 7527648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease.
    Ostronoff M; Ostronoff F; Souto Maior P; Matias C; Calixto R; Sucupira A; Domingues M; Florencio R; Tagliari C
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):729-33. PubMed ID: 16785062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
    Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
    Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined transplantation of allogeneic bone marrow and CD34+ blood cells.
    Link H; Arseniev L; Bähre O; Berenson RJ; Battmer K; Kadar JG; Jacobs R; Casper J; Kühl J; Schubert J; Diedrich H; Poliwoda H
    Blood; 1995 Oct; 86(7):2500-8. PubMed ID: 7545459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of allogeneic CD34+ blood cells.
    Link H; Arseniev L; Bähre O; Kadar JG; Diedrich H; Poliwoda H
    Blood; 1996 Jun; 87(11):4903-9. PubMed ID: 8639865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF-mobilized leukapheresis products: cellular characteristics and clinical performance in allografting.
    Dłubek D; Pacuszko T; Suchnicki K; Lange A
    J Hematother; 1999 Apr; 8(2):157-66. PubMed ID: 10349909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
    Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
    Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
    Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
    Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial.
    Szer J; Curtis DJ; Bardy PG; Grigg AP
    Aust N Z J Med; 1999 Aug; 29(4):487-93. PubMed ID: 10868525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience.
    Li L; Yin J; Li Y; Wang C; Mao X; Wei J; Cao Y; Wang N; Lin L; Xu J; Zhang Y
    Front Immunol; 2021; 12():621935. PubMed ID: 33912154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic transplants with peripheral blood progenitor cells: a report of six cases.
    Rozman C; Urbano-Ispizua A; Carreras E; Sierra J; Marin P; Rovira M; Merino A; Batlle M; Briones J; Mazzara R; Montserrat E
    Leuk Lymphoma; 1996 Feb; 20(5-6):471-4. PubMed ID: 8833405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.